Abstract. Despite the increasingly strict legislation on medicinal products, the "off-label
INTRODUCTION

S
tudies show that about 40% of medicines in adults, to over 90% in children, are used "offlabel" i.e. outside the approved summary of product characteristics [8] .
Most affected are children, mental, cancer patients and patients with rare diseases where simply there is no alternative treatment with available authorized medicinal products (drugs).
The European Medicines Agency defi nes the use of medicinal products outside their product characteristics as "situations where a medicinal product is intentionally used for a medical purpose, not in accordance with the authorised product information" [10] .
Considering that the intentionally use of medicinal products without the necessary authorization would be interpreted by the Bulgarian, respectively European, legislation as a legal violation, this phenomenon becomes a weak point of today`s drug regulation.
which clearly indicates the need of establishment of rules to regulate off-label drug use.
OBJECTIVE
To study different approaches for regulating off-label use of medicinal products in the European Union.
MATERIAL AND METHODS
Legal documents, manuals, expert opinions, scientifi c publications and the available regulatory information, which is related to the off-label use in selected European countries (France, Italy, Spain, Germany, the United Kingdom, Bulgaria) and found using electronic resources such as PubMed, Google Scholar and Google, were studied and analyzed.
RESULTS
France
In 2012, France, in order to meet the needs of public health and to control the off-label use, introduced very original temporary regulatory framework: "Temporary recommendations for use" ("Temporary Recommendations for Use", RTUs) [4] .
Between 2012 and 2014, RTUs underwent two changes, with purpose under economic reasons to circumvent the mandatory until then requirement the medicinal product allowed under this procedure not to have an authorised alternative [5] .
This amendment raises a number of resentments by the European Federation of Pharmaceutical Industries and Associations (EFPIA), according to which such actions by health authorities encourage off-label drug use.
To date, according to these "temporary recommendations for use", 13 medicinal products are allowed for off-label use [13] .
Italy
Law 648/1996 is the main legal instrument in Italy, which regulates the off-label use. According to it, certain medicinal products published in the so-called "list 648", could be used in the absence of a valid therapeutic alternative. The Italian Drug Agency (Agenzia Italiana del Farmaco, referred to as "AIFA) is obliged to maintain and periodically update this list [18] .
Over the years additional legislation is introduced (94/1998, 296/2006), which further regulates the offlabel use [12, 15] . Following the decision of the Italian authority for the protection of competition (Autorità Garante Della Concorrenza e del Mercato, called "AGCM") and in the interest of society, in 2014 Italian Government converted law 648/1996 (Legislative Decree 36/2014) into new law 79/2014, which allows and justifi es off-label use even if there is an alternative treatment [7] .
Here, as in France, the law provoked a number of reactions from the EFPIA, according to which the wide authority of the AIFA and inclusion in the "648 list" of cheaper alternatives helps maintain this type of practice.
Spain
Opposite to France and Italy, in Spain, there is no procedure by which a medicinal product can be allowed to be used off-label, but prescription outside the SmPC is regulated by Royal Decree 1015/2009 [6, 17] .
"The difference from other regulations is that is given free dom....." or "The difference from other regulations is that physicians are free to consider whether off label drug to be applied....". What is particularly is that is given freedom to the physicians responsible for the treatment to consider whether an off-label drug to be applied in a particular situation, without special permission from the drug agency. For this purpose, following conditions need to be met:
• no other medicinal product licensed in Spain, which is already authorised to be used in the specifi c indication according to its SmPC, is available;
• off-label use must be authorised by the health authority of the region where the healthcare centre is located;
• the doctor responsible for the treatment must justify in writing the reasons why the patient should use a specifi c medicinal product under off-label conditions;
• the patient must consent in writing to the off-label prescription, after having been informed about the benefi ts and risks of the treatment.
Germany
The use of a medicinal product outside the SmPC in German drug law (Arzneimittelgesetz, AMG 2005) is not considered. The law only allowed exceptions in some cases where authorization is not necessary (Section 21, Art. 1, 2 and 6) [14] .
The off-label use is determined and regulated by the Federal Joint Committee (G-BA), which was established in 2004 according to the German Social Code (Art. 92) and it involved doctors, dentists, hospitals, health insurance companies and is the highest authority in the fi eld of health [11] . G-BA has the power to update policies and take routine decisions regarding health care in Germany, including to regulate and determine the off-label prescription (according to Annex VI of the German directive on drugs) [3] . According to established procedure, the G-BA considers requests for off-label use (only for drugs already authorized in Germany) and comes with an updated "positive list", which is published for reference of physicians, health insurance companies and other interested parties [16] .
United Kingdom
Off-label drug use in the United Kingdom is not covered by basic health law (The Human Medicines Regulations 2012), but is regulated by the General Medical Council (GMC), which is an independent regulator, whose aim is to protect the health and safety of the public by ensuring proper standards in the physicians practice.
Physicians themselves are obliged to comply with the standards of good practice, set out in guidelines published by the Council, including guidelines for prescribing drugs not authorized for use in the UK, as well as those that are used outside the terms of the SmPC.
For the fi rst time, guidance that provides recommendations in this regard was established in 2008 and since then has changed several times. In the fi nal version of the guidance from 2013, medicinal products can be prescribed outside the terms of the SmPC when [9] :
• there is no suitably licensed medicine that will meet the patient's need;
• a suitably licensed medicine is not available;
• the prescribing forms are part of a properly approved research project.
Additionally, the physician must meet the following conditions:
• to be satisfi ed that there is suffi cient evidence or experience of using the medicine to demonstrate its safety and effi cacy;
• to take responsibility for prescribing the medicine and for overseeing the patient's care, monitoring, and any follow up treatment;
• to make a clear, accurate and legible record of the reasons and medicines prescribed.
Bulgaria
In Bulgaria, in the law on Medicinal Products in Human Medicine (Art. 8) there are considered situations, in which exceptionally permit is not required, but those situations do not include the off-label drug use [1] .
The use of medicinal product outside of SmPC is not covered by any other law or regulation and it practically became forbidden when the medical audit executive agency penalized leading ophthalmologists in 2014 [2] . The measures taken are showing signifi cantly different and specifi c approach. Some are within the health legislation, another are under national security legislation, while others represent guidelines of national associations (Tab. 1).
The analysis shows that none of the decisions taken for regulation is suffi ciently satisfactory and comprehensive. There are objections from doctors, patients and pharmaceutical companies, as against drugs entering into "permitted lists" for economic reasons and against the very specifi c approval procedures (Tab.
2), mainly because they could not meet the needs of patients in emergency and/or life-threatening situation, where the physician must act and take decisions very fast.
The problem concerning "off-label use" does not seem to have been found yet found its principle and universal solution, despite the huge efforts being made by regulatory authorities in different countries.
Basically, what remains unsolved, although the proposed solutions, is that in almost all countries physicians and patients still feel uncertainty in their actions when they use drugs off-label. This problem is partially resolved in the approaches of the UK and Spain, where the decision and responsibility for offlabel use, mainly lies in the hands of the physicians.
CONCLUSION
Modern medical practice and development of pharmaceutical science require all member states to introduce a regulatory framework regarding off-label drug use. Existing regulatory rules in various countries require signifi cant improvement and continuous updating. To ensure access to high quality and safe medicines for the population of the European Union it is necessary to seek a harmonized solution and approach, using the experience of applied different strategies in different member states in order to guarantee cross-border mobility of patients and health professionals.
